Key Highlights

  • Arbutus Biopharma shares closed up 9% at $5.21.
  • The company announced a modified Dutch auction tender offer to buy back as much as $230 million in common stock.
  • The tender Offer Price range is $5.00 to $5.75 per share.
  • J.P. Morgan will serve as dealer-manager, with the offer anticipated to commence on or about August 24, 2026.

Arbutus Biopharma Corporation (NASDAQ: ABUS) shares closed up 9% at $5.21 after the company announced a modified Dutch auction tender offer to buy back as much as $230 million in common stock at a price range of $5.00 to $5.75 per share.

What Happened

The move leverages the company's cash reserves to execute a significant Capital return and decrease outstanding shares. J.P. Morgan will serve as the dealer-manager for the initiative, which is anticipated to commence on or about August 24, 2026.

Market Reaction

Shares rose as investors responded to the scale of the buyback relative to the company's size, viewing the tender offer as a significant capital return using existing cash reserves.

Outlook

The commencement of the tender offer on or about August 24, 2026 represents the next disclosed step for Arbutus Biopharma's capital return program.